Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 12/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31458629 | 1.00 | KCNMA1 (0.54) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL4123552 | 0.88 | HSP90AA1 (0.51) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL31122314 | 0.88 | HSP90AA1 (0.51) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL3787046 | 0.87 | KMT2A (0.54) | MEN1KMT2AHPGDHSP90AA1HSP90AB1 | |
| SCHEMBL28738831 | 0.86 | PDK1 (0.56) | POLBMEN1KMT2AHPGDHSP90AA1 | |
| SCHEMBL4568010 | 0.84 | LMNA (0.56) | POLBMEN1KMT2AGAALMNA | |
| SCHEMBL29991673 | 0.84 | LMNA (0.56) | POLBMEN1KMT2AGAALMNA | |
| SCHEMBL2031546 | 0.84 | KCNMA1 (0.54) | KCNMA1POLBHPGDGAATP53 | |
| SCHEMBL7254652 | 0.83 | KCNMA1 (0.61) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL23954504 | 0.83 | KMT2A (0.47) | MEN1KMT2AHPGDHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785717-B1 | PYRAZOLOPYRROLIDINE COMPOUNDS | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2785717-B1 | PYRAZOLOPYRROLIDINE COMPOUNDS | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-9169221-B2 | Dihydro 1,4-benzoxazines and method of synthesizing the same using sulfonium salts | COMSATS INSTITUTE OF INFORMATION TECHNOLOGY (PK) | 2015-10-27 | — | — | US | disclosed |
| US-8969341-B2 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8969341-B2 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8969341-B2 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140323720-A1 | DIHYDRO 1,4-BENZOXAZINES AND METHOD OF SYNTHESIZING THE SAME USING SULFONIUM SALTS | COMSATS INSTITUTE OF INFORMATION TECHNOLOGY (PK) | 2014-10-30 | — | — | US | disclosed |
| EP-2785717-A1 | PYRAZOLOPYRROLIDINE COMPOUNDS | Novartis AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013080141-A1 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013080141-A1 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-20100137312-A1 | NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-06-03 | — | — | US | disclosed |
| US-20100137312-A1 | NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-06-03 | — | — | US | disclosed |
| US-20100137312-A1 | NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-06-03 | — | — | US | disclosed |
| EP-2148868-A1 | NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008138917-A1 | NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138917-A1 | NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | MDM4, MDM2, TP53 | KCNMA1 3145/4885POLB 1013/4885MEN1 152/4885 |
| US-20100137312-A1 | NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCNH1, KCNJ2, KCNN2 | KCNMA1 16/4885POLB 4819/4885MEN1 2906/4885 |
| US-20140323720-A1 | DIHYDRO 1,4-BENZOXAZINES AND METHOD OF SYNTHESIZING THE SAME USING SULFONIUM SALTS | ZYX, KDM5A, KDM4A | KCNMA1 623/4885POLB 4172/4885MEN1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.